Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT)

J Rheumatol. 2024 Apr 15:jrheum.2023-1062 doi: 10.3899/jrheum.2023-1062 Epub ahead of print

The 5-year benefit-risk profile for upadacitinib in RA remains favourable, with clinical outcomes improved or maintained through Week 260. No new safety findings were identified during the LTE. Results remained consistent with earlier analyses of SELECT-NEXT.

This study by Burmester, et al. aimed to report 5-year efficacy and safety of upadacitinib in RA from the Phase 3 LTE of SELECT-NEXT. Patients with RA were randomised 2:2:1:1 to upadacitinib 15 mg, upadacitinib 30mg, placebo to upadacitinib 15 mg, or placebo to upadacitinib 30 mg QD. All patients were switched to upadacitinib 15mg as early as Week 168.

Keywords:


Publication thumbnail: Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT)
LinkedIn